Download PDF Dr Gifford is a clinician-scientist in private practice, a peer educator, and a Visiting Research Fellow at the Queensland University of Technology, Brisbane, Australia. She is the Chair of the Clinical Management Guidelines committee of the International Myopia Institute and lead author on their report. It has taken the sum total of 18 months, countless hours, numerous drafts, around 150,000 words, more than 85 contributing authors, seven papers, an editorial and an overview to make up one landmark publication – the International Myopia Institute (IMI) White paper reports, which were published in Investigative Ophthalmology and Visual Science on February 28, 2019. In a similar spirit to the Tear Film and Ocular Surface Society Dry Eye Workshop (TFOS DEWS and DEWS II) reports, the IMI reports present peer consensus on a wide scope of topics relating to research of myopia mechanisms, product research and development, clinical and industry best practice and the public health message. The IMI reports create a clear picture of the current landscape of myopia research and practice, with an eye to the future. It is clear that the IMI Reports have come at exactly the right time. Over the past few years there has been a dramatic increase in clinician awareness, and product innovation by industry, to match research findings of a global increase in the prevalence of myopia, forecast to affect 50% of the world’s population by 2050.1 A global survey undertaken in 2015 revealed that while almost 1000 eye care practitioners (ECPs) from a dozen countries considered themselves … [ Read More ]
Myopia matters: Summarising the IMI reports
In February 2019, the International Myopia Institute published a series of reports designed to address the issues of myopia, the management of myopia in practice, to review myopia research to date, along with understanding how best to advance research in the future. In addition to Kate Gifford’s editorial, members of CORE’s clinical team have summarised each of the reports, providing an overview and key messages in each subject area. Summary: IMI – Myopia Control Reports Overview and Introduction Summary: IMI – Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies Summary: IMI – Report on Experimental Models of Emmetropization and Myopia Summary: IMI – Myopia Genetics Report Summary: IMI – Interventions for Controlling Myopia Onset and Progression Report Summary: IMI – Clinical Myopia Control Trials and Instrumentation Report Summary: IMI – Industry Guidelines and Ethical Considerations for Myopia Control Report Summary: IMI – Clinical Management Guidelines Report
Dr Noel A. Brennan is Research Fellow at Johnson & Johnson Vision, where he has been since 2011. Prior to that he co-directed a privately-owned research consulting company and, before that, was an academic faculty member at the University of Melbourne, reaching the level of Reader. Download the poster (.pdf), which was originally shared at the American Academy of Optometry (AAO) annual meeting, 2018. Evidence-Based Efficacy of Myopia Control Interventions Noel A. Brennan1 MScOptom, PhD, FAAO Xu Cheng1 MD, PhD, FAAO Mark Bullimore2 MCOptom, PhD, FAAO, FARVO 1. Johnson & Johnson Vision 2. Independent Consultant Purpose Decision-making in modern clinical practice is increasingly dependent on evidence-based medicine. Previous analyses of the efficacy of myopia control interventions have delivered results as percentage or absolute reduction in myopia progression over a given time frame. Estimates of longer term efficacy have been constructed around these estimates but fail to account for two important recent observations: (i) myopia control efficacy tends to an absolute effect rather than a relative effect across the progression range, and (ii) efficacy may decrease over time on both absolute and relative bases. Here, we apply the principles of evidence-based medicine to efficacy of myopia control interventions. Methods We systematically reviewed the literature, including relevant peer-reviewed conference abstracts, to categorize quality of investigations of a set of myopia control interventions currently of interest (see Table) based on adherence to evidence-based principles. The only indisputable metric than can be used is data-driven estimates of cumulative absolute reduction in progression rather than absolute annual or relative rates. … [ Read More ]
Wondering how to apply the clinical management report in your practice? Our roadmap, developed in conjunction with the paper’s lead author, Kate Gifford, provides a step-by-step roadmap through the guidelines. Download here.